Despite recent positive earnings and growth projections for Amgen, the company has underperformed and is currently trading near its 52-week low. I bel...
Read
More
Despite recent positive earnings and growth projections for Amgen, the company has underperformed and is currently trading near its 52-week low. I believe this presents a short opportunity, as market sentiment may not sustain the recent optimism despite the potential upside in the biotech sector.